Moore Matthew Richard 4
4 · Arcutis Biotherapeutics, Inc. · Filed Mar 6, 2024
Insider Transaction Report
Form 4
Moore Matthew Richard
SVP and Chief Business Officer
Transactions
- Sale
Common Stock
2024-03-04$11.12/sh−3,468$38,568→ 146,020 total
Footnotes (2)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units.
- [F2]The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.